Content about Management of prostate cancer

May 15, 2013

A new treatment for late-stage prostate cancer has received approval from the Food and Drug Administration.

SILVER SPRING, Md. — A new treatment for late-stage prostate cancer has received approval from the Food and Drug Administration.

The FDA announced Wednesday the approval of Bayer's Xofigo (radian Ra 223 dichloride) for men with symptomatic, castration-resistant prostate cancer that has spread to the bones but not other organs, also known as metastasis. The drug is designed for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

December 10, 2012

The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new use for a cancer drug made by Johnson & Johnson, the agency said Monday.

The FDA announced the approval of Zytiga (abiraterone acetate), made by J&J subsidiary Janssen Biotech, for men with castration-resistant prostate cancer that has spread to other parts of the body, for use prior to receiving chemotherapy. The drug was already approved for castration-resistant prostate cancer in men who had already undergone chemotherapy treatment.

August 30, 2012

Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

DALLAS — Men who have been treated for prostate cancer, either with surgery or radiation, could benefit from taking aspirin regularly, according to a multicenter study published in Tuesday's issue of the Journal of Clinical Oncology.

November 21, 2011

A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

THOUSAND OAKS, Calif. — A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.

September 30, 2010

Data published in the latest issue of medical journal The Lancet showed that a recently...

BRIDGEWATER, N.J. Data published in the latest issue of medical journal The Lancet showed that a recently approved drug reduced the risk of death in men with a certain form of prostate cancer by more than a quarter.

 

September 27, 2010

Pfizer has halted a late-stage trial of a drug therapy in men with prostate cancer,...

NEW YORK Pfizer has halted a late-stage trial of a drug therapy in men with prostate cancer, the drug maker said.

Pfizer announced the discontinuation of “SUN 1120,” a phase-3 trial of Sutent (sunitinib malate) combined with the generic drug prednisone in men with advanced castration-resistant prostate cancer that had progressed despite chemotherapy. An analysis of data from the trial found that the men were not more likely to improve overall survival when taking the two drugs together than when they took prednisone alone.

 

June 16, 2010

The Food and Drug Administration has approved a new treatment for advanced prostate cancer, the...

May 2, 2010

The Food and Drug Administration is investigating a possible link between drugs commonly used to...

February 8, 2010

An investigational drug made by Amgen for treating prostate cancer that had spread to the...